SCHEMBL25311355

SCHEMBL25311355

CCOC(=O)CC1CCCCCCCCCCCCCC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 6/20 0.45
ALDH1A1 P00352 3/20 0.45
KMT2A Q03164 3/20 0.45
GAA P10253 2/20 0.44
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
POLB P06746 1/20 0.43
LMNA P02545 1/20 0.43
MEN1 O00255 1/20 0.43
EPHX1 P07099 1/20 0.42
HPGD P15428 1/20 0.42
THRB P10828 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9134377 1.00 TDP1 (0.50) TDP1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL18797 1.00 TDP1 (0.50) TDP1L3MBTL1ALDH1A1KMT2AGAA
Cyclohexane SCHEMBL28249403 1.00 TDP1 (0.50) TDP1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL26914635 1.00 TDP1 (0.50) TDP1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL9131994 1.00 TDP1 (0.50) TDP1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL2779505 1.00 TDP1 (0.50) TDP1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL29071102 0.98 TDP1 (0.49) TDP1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL1439129 0.98 TDP1 (0.48) TDP1L3MBTL1ALDH1A1KMT2AGAA
Acetic Acid SCHEMBL17748838 0.94 TDP1 (0.47) TDP1L3MBTL1ALDH1A1KMT2AGAA
SCHEMBL1881523 0.94 ALDH1A1 (0.46) TDP1L3MBTL1ALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119698302-A Lipid nanoparticles 国立大学法人北海道大学 2025-03-25 CN disclosed
WO-2025035202-A1 IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2025-02-20 WO disclosed
US-20230365602-A1 COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND QUADREL S.R.L. (IT) 2023-11-16 US disclosed
WO-2023188830-A1 LIPID NANOPARTICLES 国立大学法人北海道大学 2023-10-05 WO disclosed
EP-4216960-A1 COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND Quadrel S.r.l. (IT) 2023-08-02 EP disclosed
WO-2022063790-A1 COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND QUADREL S.R.L. (IT) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365602-A1 COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND PIGO, PIGS, AGPS TDP1 4619/4885L3MBTL1 2915/4885ALDH1A1 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.